G1 Pro

UltraPlex Proteomics Platform

The Nanomation™ G1 Pro can process up to 96 samples in a single run, facilitating large-scale proteomics cohort studies.

It reduces the sample pretreatment time from 2-3 days to just 8-9 hours, allowing customers to expedite their projects efficiently.

Get ready to meet the ALL-IN-ONE solution hansforming automated proteomics.

An autonomous robot streamlining workflows with precision and efficiency.

A powerful data generator delivering high-quality proteomics insights.

An integrated app station advancing lab automation for seamless operations.

Features

Automated

Built-in standard workflows, one-click start

Open

Ability to create customized workflows

High throughput

Up to 96 samples

per run

Proteonano™ G1 Pro Proteomics Workstation

Applications

Discovery of Protein Biomarkers

Detection of diseases through bodily fluids such as blood, is increasingly becoming the mainstream approach for clinical screening and diagnosis. Currently, there are already 100-200 plasma proteins approved by the FDA as disease biomarkers.

Clinical Trial Patient Screening & Stratification

Large-scale plasma proteomics discovery aids in more accurate patient screening, understanding patient characteristics, and identifying additional biomarkers. This enhances the accuracy and reliability of clinical trials, providing more guidance and information for clinical practice.

New Target
Discovery

Proteins are key to cellular functions and reflect gene expression levels. Recent advances in mass spectrometry-based proteomics have opened new possibilities for studying disease mechanisms and discovering therapeutic targets.

Drug Efficacy Prediction and Assessment

Proteomics is widely employed in clinical drug efficacy assessment. Through proteomic techniques, the impact of drugs on proteins within the human body can be thoroughly studied, enabling the evaluation of drug efficacy and side effects.